Skip to content

Study · Randomized controlled trial · n = 30 · 2021

5 results

Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study.

Kumarathurai P, Sajadieh A, Anholm C, Kristiansen OP, Haugaard SB, Nielsen OW

Cardiovascular diabetology7 Jan 2021Cited by 16 (Europe PMC)

PMID33413428 (opens in a new tab)PMCIDPMC7791686 (opens in a new tab)DOI10.1186/s12933-020-01205-2 (opens in a new tab)PepBankPUB-33413428
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

BackgroundDiastolic dysfunction is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with overweight, glucose dysregulation and coronary artery disease (CAD). The GLP-1 receptor agonist, liraglutide, has shown to induce weight loss and improve metabolic factors, thus modulating factors associated with diastolic dysfunction. We have previously reported the effects of liraglutide on systolic function, and in this current study we explore the effects of liraglutide on diastolic function parameters in patients with stable CAD, preserved left ventricular ejection fraction (LVEF), and newly diagnosed T2DM.MethodsThirty subjects were randomized to liraglutide or placebo intervention for 12 + 12-weeks in this double-blind cross-over study. 2D-echocardiography using tissue velocity imaging was used for assessment of diastolic function parameters. Early diastolic filling velocity (E), late atrial filling velocity (A), E-wave deceleration time (EDT) and E/A ratio was assessed from the pulse wave (PW)-Doppler velocity recording of the mitral inflow. Peak early diastolic annular velocities (e') was measured from color tissue doppler images.ResultsLiraglutide, when compared to placebo, induced a significant reduction in average e' and lateral e' velocities (- 0.57 cm/s [- 1.05 to - 0.08] and -0.74 cm/s [-1.32 to -0.15], respectively). Adjusted for the concomitant increase in HR (+ 6.16 bpm [0.79 to 11.54], the changes were not significant. No significant changes in other diastolic function parameters were observed.ConclusionsLiraglutide therapy did not improve any diastolic function parameters in subjects with T2DM, CAD, and preserved LVEF. Instead, a deterioration in e' was observed, which was associated to an increase in heart rate induced by liraglutide therapy. Trial registration Clinical Trial Registration: http://www.clinicaltrials.gov (unique identifier: NCT01595789) (first submitted May 8, 2012).
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and stable coronary artery disease, liraglutide significantly reduced average e' velocity compared with placebo.

    In plain wordsIn adults with type 2 diabetes and heart artery disease, liraglutide lowered a heart relaxation measure (average e') more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseAverage e' velocity
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Difference in average e'
    −0.57 cm/s
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide, when compared to placebo, induced a significant reduction in average e' and lateral e' velocities (- 0.57 cm/s [- 1.05 to - 0.08] and -0.74 cm/s [-1.32 to -0.15], respectively).
    1 context sentence
    Summary · context
    Thirty subjects were randomized to liraglutide or placebo intervention for 12 + 12-weeks in this double-blind cross-over study.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and stable coronary artery disease, liraglutide significantly reduced lateral e' velocity compared with placebo.

    In plain wordsIn adults with type 2 diabetes and heart artery disease, liraglutide lowered a heart relaxation measure (lateral e') more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseLateral e' velocity
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Difference in lateral e'
    −0.74 cm/s
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide, when compared to placebo, induced a significant reduction in average e' and lateral e' velocities (- 0.57 cm/s [- 1.05 to - 0.08] and -0.74 cm/s [-1.32 to -0.15], respectively).
    1 context sentence
    Summary · context
    Thirty subjects were randomized to liraglutide or placebo intervention for 12 + 12-weeks in this double-blind cross-over study.
  3. 03HumanRandomized controlled trialEfficacy outcome

    After adjustment for the increase in heart rate, the reductions in e' velocities with liraglutide were not significant.

    In plain wordsAfter accounting for a faster heart rate, the drop in the heart relaxation measure with liraglutide was no longer significant.

    Peptide
    Liraglutide
    Outcome
    No significant changee' velocities adjusted for heart rate
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Adjusted for the concomitant increase in HR (+ 6.16 bpm [0.79 to 11.54], the changes were not significant.
    1 context sentence
    Summary · context
    Thirty subjects were randomized to liraglutide or placebo intervention for 12 + 12-weeks in this double-blind cross-over study.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and stable coronary artery disease, liraglutide did not significantly change the other diastolic function parameters compared with placebo.

    In plain wordsIn adults with type 2 diabetes and heart artery disease, liraglutide did not change the other heart relaxation measures compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeOther diastolic function parameters
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant changes in other diastolic function parameters were observed.
    1 context sentence
    Summary · context
    Thirty subjects were randomized to liraglutide or placebo intervention for 12 + 12-weeks in this double-blind cross-over study.
  5. 05HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes and stable coronary artery disease, liraglutide increased heart rate compared with placebo.

    In plain wordsIn adults with type 2 diabetes and heart artery disease, liraglutide raised heart rate compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseHeart rate
    Study

    n = 30

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Difference in heart rate
    6.16 bpm
    liraglutide vs placebo

    Source sentences

    Summary
    the concomitant increase in HR (+ 6.16 bpm [0.79 to 11.54]
    1 context sentence
    Summary · context
    Thirty subjects were randomized to liraglutide or placebo intervention for 12 + 12-weeks in this double-blind cross-over study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01595789

The Effect of Liraglutide on the Treatment of Coronary Artery Disease and Type 2 Diabetes

Haugaard, Steen Bendix, M.D., DMScn = 41May 2012 to Jul 2015

Coronary Artery Disease · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 7 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.